Skip to main content
Download PDF

Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer

Breast Cancer Research volume 22, Article number: 14 (2020) Cite this article

The Original Article was published on 04 December 2019

Correction to: Breast Cancer Research (2019) 21:135

https://doi.org/10.1186/s13058-019-1222-0

After publication of the original article [1], we were notified that an author’s surname has been erroneously spelled. Elisabetta Maragoni’s family name should be replaced with Marangoni.

Reference

  1. Pancholi S, et al. Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer. Breast Cancer Res. 2019;21:135. https://doi.org/10.1186/s13058-019-1222-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, SW7 3RP, UK

    Sunil Pancholi, Mariana Ferreira Leal, Ricardo Ribas, Nikiana Simigdala, Eugene Schuster, Lila Zabaglo, Qiong Gao & Lesley-Ann Martin

  2. BioPole Alfort, Ecole Nationale Veterinaire d’Alford, Maisons Alfort, France

    Sophie Chateau-Joubert

  3. Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital, London, SW3 6JJ, UK

    Margaret Hills, Andrew Dodson & Mitch Dowsett

  4. Breast Unit, Royal Marsden Hospital, London, SW3 6JJ, UK

    Stephen R. Johnston

  5. Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK

    Sabina C. Cosulich

  6. Department of Translational Research, Institut Curie, Paris, France

    Elisabetta Marangoni

Authors
  1. Sunil Pancholi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mariana Ferreira Leal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ricardo Ribas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nikiana Simigdala
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eugene Schuster
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sophie Chateau-Joubert
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lila Zabaglo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Margaret Hills
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Andrew Dodson
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Qiong Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Stephen R. Johnston
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Mitch Dowsett
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Sabina C. Cosulich
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Elisabetta Marangoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Lesley-Ann Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lesley-Ann Martin.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pancholi, S., Leal, M.F., Ribas, R. et al. Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer. Breast Cancer Res 22, 14 (2020). https://doi.org/10.1186/s13058-020-1254-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s13058-020-1254-5

Breast Cancer Research

ISSN: 1465-542X

Contact us